Table 2:
N=160 | Control Group (n=80) | Intervention Group (n=80) | P-value |
---|---|---|---|
| |||
Discussed with MD/CNM/GC how prenatal genetic information can be used, stored, and shared | 0.081 | ||
Yes | 17 (21.3) | 8 (10.0) | |
No | 63 (78.8) | 72 (90.0) | |
| |||
Importance of knowing early on whether pregnancy affected by Down Syndrome | 0.371 | ||
Not important | 2 (2.5) | 0 (--) | |
Not really important | 1 (1.3) | 4 (5.0) | |
Somewhat important | 22 (27.5) | 22 (27.5) | |
Very important | 55 (68.8) | 54 (67.5) | |
| |||
Importance of prenatal care provider’s recommendation | (n=79) | (n=78) | 0.931 |
Not important | 0 (--) | 0 (--) | |
Not really important | 5 (6.3) | 5 (6.4) | |
Somewhat important | 27 (34.2) | 29 (37.2) | |
Very important | 47 (59.5) | 44 (56.4) | |
| |||
Importance of early fetal sex detection | 0.291 | ||
Not important | 14 (17.5) | 12 (15.0) | |
Not really important | 9 (11.3) | 17 (21.3) | |
Somewhat important | 32 (40.0) | 24 (30.0) | |
Very important | 25 (31.3) | 27 (33.8) | |
| |||
Prior to blood draw, patient aware that multiple companies offer cfDNA testing | 0.741 | ||
Yes | 27 (33.8) | 24 (30.0) | |
No | 53 (66.3) | 56 (70.0) | |
| |||
Prior to blood draw, patient researched cfDNA companies | (n=27) | (n=24) | 1.001 |
Yes | 4 (14.8) | 3 (12.5) | |
No | 23 (85.2) | 21 (87.5) | |
| |||
Factors that influenced selection of cfDNA screening company* | |||
MD/GC/CNM† recommendation | 73 (91.3) | 73 (91.3) | 1.001 |
Covered by insurance | 14 (17.5) | 16 (20.0) | 0.841 |
Test performance | 3 (3.8) | 4 (5.0) | 1.001 |
Genetic privacy concerns | 1 (1.3) | 0 (--) | 1.001 |
Other | 2 (2.5) | 3 (3.8) | 1.001 |
Categorical data are (N%);
Fisher’s exact test;
Check all that apply, does not sum to 100%;
Physician, genetic counselor, certified nurse-midwife.